Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

NCT01514864 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT01514864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01514864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2012
Completion date
July 23, 2014
Enrollment
19 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung